Sansone Christopher R.
Known title: DirectorCIK: 0001519525
Associated companies
Transaction History
| INFU | ▼ Sell | Open Market | 40,000 | $322K | 11/21/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 40,838 | $334K | 11/17/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 25,000 | $50K | 2/17/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 80,000 | $1.4M | 11/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.